Pharma's 2026 predictions revisited: AI tools have arrived, but organizational readiness, data governance, and regulatory gaps now limit real-world impact.
Remco Munnik
Advertisement
Founder and Owner
Aracana Life Sciences
Articles by Remco Munnik
Pharma's 2026 predictions revisited: AI tools have arrived, but organizational readiness, data governance, and regulatory gaps now limit real-world impact.
Pharma manufacturing and development experts reassess their 2026 predictions for the industry and look ahead to the second half of the year.
Six months in, pharma manufacturing and development experts reassess their 2026 outlooks and predict what comes next.
Arcana Life Sciences' Remco Munnik revisits his 2026 predictions on EU regulatory reform, AI adoption, and data governance, and previews pharma's biggest challenges for H2 2026.
Advertisement
Latest Updated Articles
H1 2026 in Review: AI Adoption, Onshoring, and Data GapsAugust 3rd 2026
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
4
France Remains One of Europe’s Leading Biotech Funding Hubs
5